100 related articles for article (PubMed ID: 9066768)
1. Chloropeptins, new anti-HIV antibiotics inhibiting gp120-CD4 binding from Streptomyces sp. II. Structure elucidation of chloropeptin I.
Matsuzaki K; Ogino T; Sunazuka T; Tanaka H; Omura S
J Antibiot (Tokyo); 1997 Jan; 50(1):66-9. PubMed ID: 9066768
[TBL] [Abstract][Full Text] [Related]
2. Chloropeptins, new anti-HIV antibiotics inhibiting gp120-CD4 binding from Streptomyces sp. I. Taxonomy, fermentation, isolation, and physico-chemical properties and biological activities.
Tanaka H; Matsuzaki K; Nakashima H; Ogino T; Matsumoto A; Ikeda H; Woodruff HB; Omura S
J Antibiot (Tokyo); 1997 Jan; 50(1):58-65. PubMed ID: 9066767
[TBL] [Abstract][Full Text] [Related]
3. Chloropeptins I and II, novel inhibitors against gp120-CD4 binding from Streptomyces sp.
Matsuzaki K; Ikeda H; Ogino T; Matsumoto A; Woodruff HB; Tanaka H; Omura S
J Antibiot (Tokyo); 1994 Oct; 47(10):1173-4. PubMed ID: 7961171
[No Abstract] [Full Text] [Related]
4. The complestatins as HIV-1 integrase inhibitors. Efficient isolation, structure elucidation, and inhibitory activities of isocomplestatin, chloropeptin I, new complestatins, A and B, and acid-hydrolysis products of chloropeptin I.
Singh SB; Jayasuriya H; Salituro GM; Zink DL; Shafiee A; Heimbuch B; Silverman KC; Lingham RB; Genilloud O; Teran A; Vilella D; Felock P; Hazuda D
J Nat Prod; 2001 Jul; 64(7):874-82. PubMed ID: 11473415
[TBL] [Abstract][Full Text] [Related]
5. Short peptides with induced beta-turn inhibit the interaction between HIV-1 gp120 and CD4.
Choi YH; Rho WS; Kim ND; Park SJ; Shin DH; Kim JW; Im SH; Won HS; Lee CW; Chae CB; Sung YC
J Med Chem; 2001 Apr; 44(9):1356-63. PubMed ID: 11311058
[TBL] [Abstract][Full Text] [Related]
6. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.
Biorn AC; Cocklin S; Madani N; Si Z; Ivanovic T; Samanen J; Van Ryk DI; Pantophlet R; Burton DR; Freire E; Sodroski J; Chaiken IM
Biochemistry; 2004 Feb; 43(7):1928-38. PubMed ID: 14967033
[TBL] [Abstract][Full Text] [Related]
7. The design of a specific ligand of HIV gp120.
Scarselli M; Facchiano A; Russo G; Molinari H; Ragona L; Zetta L; Niccolai N
J Pept Sci; 1997; 3(5):383-90. PubMed ID: 9391913
[TBL] [Abstract][Full Text] [Related]
8. CD4-derived synthetic peptide blocks the binding of HIV-1 GP120 to CD4-bearing cells and prevents HIV-1 infection.
Shapira-Nahor O; Golding H; Vujcic LK; Resto-Ruiz S; Fields RL; Robey FA
Cell Immunol; 1990 Jun; 128(1):101-17. PubMed ID: 1971526
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of diastereomers of complestatin and chloropeptin I: substrate-dependent atropstereoselectivity of the intramolecular Suzuki-Miyaura reaction.
Jia Y; Bois-Choussy M; Zhu J
Angew Chem Int Ed Engl; 2008; 47(22):4167-72. PubMed ID: 18404759
[No Abstract] [Full Text] [Related]
10. Computational Design of Hypothetical New Peptides Based on a Cyclotide Scaffold as HIV gp120 Inhibitor.
Sangphukieo A; Nawae W; Laomettachit T; Supasitthimethee U; Ruengjitchatchawalya M
PLoS One; 2015; 10(11):e0139562. PubMed ID: 26517259
[TBL] [Abstract][Full Text] [Related]
11. Total synthesis of complestatin (chloropeptin II).
Wang Z; Bois-Choussy M; Jia Y; Zhu J
Angew Chem Int Ed Engl; 2010 Mar; 49(11):2018-22. PubMed ID: 20148426
[No Abstract] [Full Text] [Related]
12. A new class of viral inhibitor.
Nat Biotechnol; 1997 Feb; 15(2):135. PubMed ID: 9035136
[No Abstract] [Full Text] [Related]
13. Zelkovamycin, a new cyclic peptide antibiotic from Streptomyces sp. K96-0670. II. Structure elucidation.
Tabata N; Tomoda H; Zhang H; Uchida R; Omura S
J Antibiot (Tokyo); 1999 Jan; 52(1):34-9. PubMed ID: 10092195
[TBL] [Abstract][Full Text] [Related]
14. Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120.
Férir G; Hänchen A; François KO; Hoorelbeke B; Huskens D; Dettner F; Süssmuth RD; Schols D
Virology; 2012 Nov; 433(2):308-19. PubMed ID: 22959895
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
Keller PW; Morrison O; Vassell R; Weiss CD
J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
[TBL] [Abstract][Full Text] [Related]
16. The Ixodes scapularis salivary protein, salp15, prevents the association of HIV-1 gp120 and CD4.
Juncadella IJ; Garg R; Bates TC; Olivera ER; Anguita J
Biochem Biophys Res Commun; 2008 Feb; 367(1):41-6. PubMed ID: 18162176
[TBL] [Abstract][Full Text] [Related]
17. Macrocyclic Envelope Glycoprotein Antagonists that Irreversibly Inactivate HIV-1 before Host Cell Encounter.
Rashad AA; Kalyana Sundaram RV; Aneja R; Duffy C; Chaiken I
J Med Chem; 2015 Sep; 58(18):7603-8. PubMed ID: 26331669
[TBL] [Abstract][Full Text] [Related]
18. A defined conformational epitope from the C4 domain of HIV type 1 glycoprotein 120: anti-cyclic C4 antibodies from HIV-positive donors magnify glycoprotein 120 suppression of interleukin 2 produced by T cells.
Robey FA; Robert-Guroff M
AIDS Res Hum Retroviruses; 2001 Apr; 17(6):533-41. PubMed ID: 11350667
[TBL] [Abstract][Full Text] [Related]
19. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.
Yang QE; Stephen AG; Adelsberger JW; Roberts PE; Zhu W; Currens MJ; Feng Y; Crise BJ; Gorelick RJ; Rein AR; Fisher RJ; Shoemaker RH; Sei S
J Virol; 2005 May; 79(10):6122-33. PubMed ID: 15857997
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
